PDIGREE trial: what clinicians have said so far
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
- NCT03793166 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on PDIGREE (cabozantinib plus nivolumab in untreated metastatic clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 20 most recent indexed sources
Automated from the 20 newest of 21 indexed sources (May 2019 – Oct 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether adding cabozantinib to nivolumab after induction improves overall survival in patients without complete response or progression
- Whether early response after ipilimumab-nivolumab induction reliably guides the choice of subsequent treatment
- How the complete response rate with ipilimumab-nivolumab induction compares with earlier first-line ipilimumab-nivolumab data
- Whether cabozantinib is an effective next step after progression on ipilimumab-nivolumab induction
Indexed commentary on PDIGREE so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 20 posts on X, typically up to 88 once built | |
| 1 post on Bluesky, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Lymph Nodes; Metastatic Malignant Neoplasm in the Soft Tissue; Metastatic Malignant Neoplasm in the Viscera; Rhabdoid Tumor of the Kidney; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection; Bone Scan; Cabozantinib; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm A (nivolumab) · Active comparator
- Arm B (nivolumab, cabozantinib) · Experimental
- Enrollment
- 1,175 (estimated)
- Primary outcomes
- Overall survival (OS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jun 7, 2019
- Primary completion
- Mar 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT03793166 · updated Nov 12, 2026
Publications
linked from the registry- Labriola MK, George DJ. Setting a new standard for long-term survival in metastatic kidney cancer. Cancer. 2022 Jun 1;128(11):2058-2060. doi: 10.1002/cncr.34177. Epub 2022 Apr 5. No abstract available. PubMed 35383907
- Yang Y, Psutka SP, Parikh AB, Li M, Collier K, Miah A, Mori SV, Hinkley M, Tykodi SS, Hall E, Thompson JA, Yin M. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Cancer Med. 2022 Aug;11(16):3106-3114. doi: 10.1002/cam4.4679. Epub 2022 Mar 18. PubMed 35304832